Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 4-amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl-2,2,3,3,5,5,6,6-d8)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one
Purity: ≥99% deuterated forms (d1-d8)
Formula Markup: C21H13D8FN6O
Formula Weight: 400.478163
CAS Number: 1246819-84-0
Notes: Dovitinib-d8 is intended for use as an internal standard for the quantification of dovitinib (Item No. 15220) by GC- or LC-MS. Dovitinib is a multi-kinase inhibitor.{47801} It inhibits the receptor tyrosine kinases FLT3, CSF1R, and c-Kit (IC50s = 1, 36, and 2 nM, respectively), as well as FGFR1, FGFR3, VEGFR1-3, PDFGRα, and PDGFRβ (IC50s = 8, 9, 10, 13, 8, 27, and 210 nM, respectively). Dovitinib inhibits proliferation of human multiple myeloma cell lines expressing mutant, but not wild-type, FGFR3 (IC50s = 90-550 and >2,500 nM, respectively). It decreases FGF-induced ERK1/2 phosphorylation and induces apoptosis in patient-derived multiple myeloma cells when used at a concentration of 500 nM. Dovitinib (3-300 mg/kg for eight days) inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice.{24514} It reduces tumor growth in KM12L4A colon, DU145 prostate, and MV4-11 acute myelogenous leukemia mouse xenograft models with ED50 values of 17, 23, and 3 mg/kg per day, respectively.
Deutsch
English
